Latvia vs Qatar: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Latvia
0.0%
in 2024
Qatar
0.0%
in 2024
Latvia rank
143rd
Qatar rank
143rd
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Latvia
- Qatar
How they compare
Latvia currently reports 0.0% against 0.0% in Qatar, a difference of 0.0%.
Across all 10 years both countries report, Qatar has been ahead every year.
Latvia ranks 143rd and Qatar ranks 143rd of 215 countries.
Qatar has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Latvia | Qatar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Qatar |
| 2020s | 0.0% | 0.0% | 0.0% | Qatar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Latvia or Qatar?
- Latvia, at 0.0% against 0.0% in Qatar as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Latvia and Qatar?
- 0.0%, with Latvia ahead.
- How many years of comparable data are there for Latvia and Qatar?
- 10 years are reported by both, from 2015 to 2024.
- How do Latvia and Qatar rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Latvia ranks 143rd and Qatar ranks 143rd of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.